I think there have been other examples where there hasn't been quick action by the regulator because there's been a dispute or a discussion about whether the harm is clearly owing. Diane-35 was another medication that's commonly used to treat acne that has received some attention in the last year or so. Really the delay that people were concerned about stems from a lack of a power to issue a recall without the permission of the manufacturer. That's what's in this bill.
That's one example. I don't know if Dr. Lexchin can offer others.